Boston Scientific Corporation (BSX) earnings on October 28, 2026
More Boston Scientific Corporation earnings
Prior outlook: Optimistic Outcome: Missed
Boston Scientific shares fell sharply after earnings, dropping as much as 14.34% intraday before closing down 5.84%. Concerns about a lower outlook weighed on the stock.
BSX price around the earnings
42.43
Change: -5.8%
2026-10-28, 20:00 UTC
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- Starting price
Prior thesis
Prior outlook: Optimistic Outcome: Missed
- Thesis published
- Results released
The price setup points optimistic and outweighed more cautious positioning: recent gains and stronger performance versus the broader market support the outlook, even though analyst price targets sit below the current price and crowd optimism is extreme.
Context analyzed before publication
- Playbook
- Recent price performance and expected company growth remain favorable, while mixed analyst actions and negative post-earnings reactions keep the backdrop uneven.
- Trend
- Analyst confidence improved sharply in recent sessions
Analysts
Drivers
-
Analysts
Negative
The average analyst price target of $58 is below the current $64.60, and Stifel recently lowered its target to $55, showing caution even though most analysts point to an optimistic scenario.
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 1.6
- Analysts covering the stock
- 28
- Average price target
- 57.82
- Lowest price target
- 44
- Highest price target
- 78
- Upside to price target
- 28.3%
- Quarterly earnings growth
- 13.8%
- Revenue growth
- 7.5%
- Forward EPS
- 3.38
- Trailing EPS
- 2.47
- Analyst moves in the last 60 days
- 8
- Strong buy: 6
- Buy: 18
- Hold: 6
- Sell: 0
- Strong sell: 0
- Strong buy
- 6
- Buy
- 18
- Hold
- 6
- Sell
- 0
- Strong sell
- 0
- October 26, 2026 · Stifel: Maintains rating (Buy → Buy)
- October 14, 2026 · Truist Securities: Maintains rating (Buy → Buy)
- October 7, 2026 · Barclays: Initiates coverage (Equal-Weight)
- October 5, 2026 · Citigroup: Maintains rating (Neutral → Neutral)
- September 24, 2026 · Wells Fargo: Maintains rating (Equal-Weight → Equal-Weight)
- September 21, 2026 · Oppenheimer: Maintains rating (Outperform → Outperform)
- September 17, 2026 · Citigroup: Downgrades rating (Buy → Neutral)
- September 9, 2026 · BTIG: Maintains rating (Buy → Buy)
News and sentiment
Drivers
-
News & sentiment
Negative
Retail sentiment is extremely crowded on the optimistic side, at 85.71% in a small sample, which conflicts with the pessimistic scenario indicated by analyst price targets. The overall scenario remains optimistic.
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- High
- Normalized volume
- 99%
- Messages
- 30
News
Sources (7)
- Stifel Maintains Buy on Boston Scientific, Lowers Price Target to $55 (opens in a new tab) — Benzinga
- Boston Scientific to Participate in Stifel's 2026 Healthcare Conference (opens in a new tab) — fiscal.ai
- Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $51 (opens in a new tab) — Benzinga
- Barclays Initiates Coverage On Boston Scientific with Equal-Weight Rating, Announces Price Target of $48 (opens in a new tab) — Benzinga
- Boston Scientific Appoints Joseph M. Fitzgerald As EVP And COO, Effective January 1, 2027 (opens in a new tab) — Benzinga
- If You Invested $1000 In Boston Scientific Stock 15 Years Ago, You Would Have This Much Today (opens in a new tab) — Benzinga
- Elutia Obtains $8M Payment from Boston Scientific; Co. Now Fully Funded into 2029 (opens in a new tab) — Benzinga
Technicals
Drivers
-
Technical
Positive
Trend strength is positive over 14 days (+4.08%) and 30 days (+2.64%), and price performance has exceeded the S&P 500 by 2.85%, supporting a constructive near-term outlook.
Evidence
- Price when the context was analyzed
- 45.08
- Average true range (ATR)
- 2.5%
- Distance to 52-week high
- -57.1%
- 14-day change (14d)
- +4.1%
- 30-day change (32d)
- +2.6%
- 30-day relative strength
- +2.9%
- SPY change (32d)
- -0.2%
- Nearest support
- 44.8
- Distance to nearest support
- 0.6%
- Nearest resistance
- 45.1
- Distance to nearest resistance
- 0.1%
- Volume accumulation ratio (14d / 46d)
- 0.79
- Mid: 44.8 (0.6% away, 0.25 ATR, 14 touches)
- Mid: 44.38 (1.6% away, 0.63 ATR, 32 touches)
- Major: 43.93 (2.6% away, 1.03 ATR, 43 touches)
- Mid: 45.1 (0.1% away, 0.02 ATR, 36 touches)
- Mid: 45.42 (0.8% away, 0.31 ATR, 13 touches)
- Mid: 45.78 (1.6% away, 0.64 ATR, 22 touches)
Trends
Evidence
- Average earnings surprise
- +3.3%
- July 29, 2026: actual EPS 0.86 vs estimate 0.83 (surprise +3.9%)
- April 22, 2026: actual EPS 0.8 vs estimate 0.79 (surprise +1.6%)
- February 4, 2026: actual EPS 0.8 vs estimate 0.78 (surprise +2.4%)
- October 22, 2025: actual EPS 0.75 vs estimate 0.71 (surprise +5.1%)
Expected move
Drivers
-
Past earnings
Negative
The last two earnings reports were followed by price drops of 11.5% on February 4, 2026, and 7.5% on July 29, 2026. This recurring reaction occurred despite better-than-expected earnings per share, although the scenario remains optimistic.
- Implied move
- +7.2%
- Source
- Options chain
Reactions over its last 21 earnings
- Median move
- 2.8%
- 75th percentile move
- 4.4%
- 90th percentile move
- 6.2%
- Up / down moves
- 13 / 8
- Average up move
- +3.6%
- Average down move
- -3.3%
Monitoring and close
What Boston Scientific Corporation reported
- Status
- Finished
| Actual EPS | 0.73 |
|---|---|
| EPS estimate | 0.72 |
| EPS surprise | +1.4% |
| Revenue | $5,138 million |
| Revenue estimate | $5,046 million |
| Revenue surprise | +1.8% |
Boston Scientific cut its 2026 guidance for the third time following a cybersecurity incident. Third-quarter revenue rose and beat estimates, but margins weakened and shares fell.
Sources (30)
- Boston Scientific Corporation Q3 2026 Earnings Call Summary (opens in a new tab) — Yahoo
- Boston Scientific (BSX) Q3 2026 Earnings Call Transcript (opens in a new tab) — Yahoo
- Needham Maintains Buy on Boston Scientific, Lowers Price Target to $48 (opens in a new tab) — Benzinga
- Boston Scientific Crashes As Cybersecurity Attack Weighs On Guide (opens in a new tab) — Yahoo
- Boston Scientific cuts 2026 guidance for third time this year (opens in a new tab) — Yahoo
- BSX Q3 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down (opens in a new tab) — Yahoo
- Boston Scientific Lowers Full-Year Outlook Amid Cyberattack Impact (opens in a new tab) — Yahoo
- Boston Scientific Overshadowed by Hackers, Headwinds, and Lower Guidance (opens in a new tab) — Benzinga
- BSX Stock Crashes To 4-Year Lows: Boston Scientific Sees Q4 Sales Declining, CEO Remains Confident In ‘Long-Term Strategy’ (opens in a new tab) — Yahoo
- Boston Scientific Corporation Reports Third Quarter 2026 Results (opens in a new tab) — Fintel
- Boston Scientific Shares Fall 3.5% as Earnings Miss and Lower Guidance Offset Revenue Growth (opens in a new tab) — Yahoo
- S&P 500 Premarket Movers for Oct. 28, 2026 (opens in a new tab) — ChartMill
- Boston Scientific cuts annual forecast after quarterly profit falls (opens in a new tab) — Yahoo
- Boston Scientific Q3 2026 Earnings Call Transcript (opens in a new tab) — Benzinga
- Boston Scientific Crashes 11% As Cybersecurity Attack Weighs On Guide (opens in a new tab) — Yahoo
- Boston Scientific Corporation (BSX) Q3 2026 Earnings Call Transcript (opens in a new tab) — SeekingAlpha
- Boston Scientific Falls on Sales Hit After August Cyberattack (opens in a new tab) — Yahoo
- Compared to Estimates, Boston Scientific (BSX) Q3 Earnings: A Look at Key Metrics (opens in a new tab) — Yahoo
- Boston Scientific Exec Says Expects Top-Line Pressure To Persist Into 2027, Making Revenue, EPS Growth Challenging Excluding Penumbra Deal (opens in a new tab) — Benzinga
- Boston Scientific (NYSE:BSX) Q3 2026 Results In Line, Stock Slips Premarket (opens in a new tab) — ChartMill
- Boston Scientific Exec Says Sees 200-300 Bps Q4 Hit From Cyber Incident; Expects Q4 Organic Revenue Decline In The Range Of -1% To -3%; There Will Be Additional Price Headwinds In China In 2027, And The Growth Likely Won't Be Enough To Offset The Pressure From Ep And Watchman Next Year (opens in a new tab) — Benzinga
- Boston Scientific Reports Third Quarter 2026 Financial Results (opens in a new tab) — fiscal.ai
- Boston Scientific Warned You. It Slashed Earnings Guidance After Cyberattack Hits Business. (opens in a new tab) — Yahoo
- Boston Scientific (NYSE:BSX) posts better-than-expected sales in Q3 2026 but quarterly revenue guidance misses expectations (opens in a new tab) — Yahoo
- Boston Scientific (BSX) Q3 Earnings Match Estimates (opens in a new tab) — Yahoo
- Boston Scientific Lowers FY2026 Adj EPS Guidance from $3.28-$3.32 to $3.16-$3.18 vs $3.23 Est; Lowers FY2026 Sales Guidance from $21.178B-$21.379B to $20.927B vs $21.143B Est (opens in a new tab) — Benzinga
- Boston Scientific Sees Q4 Adj EPS $0.77-$0.79 vs $0.84 Est; Sees Sales $5.127B-$5.233B vs $5.404B Est (opens in a new tab) — Benzinga
- Boston Scientific reported adjusted EPS of $0.73, above the $0.72 estimate, and sales of $5.138 billion, beating the $5.046 billion expectation. — Benzinga
- Boston Scientific Q3 Adj. EPS $0.73 Beats $0.72 Estimate, Sales $5.138B Beat $5.046B Estimate (opens in a new tab) — Benzinga
- Boston Scientific announces results for third quarter 2026 (opens in a new tab) — Yahoo
Pre-market second reading after the results
- Verdict
- Beat expectations
Heading into the open, Results beat expectations on both earnings and revenue and the price is indicating -12.9% pre-market, a move 5x the stock's usual reaction (about 3%). The figures overturn the prior optimistic scenario. Across our market history, in the 458 similar cases the close held that direction 94% of the time.
How the stock reacted
- Outcome
- Missed
- Consolidated
- -5.8%
- Max favorable move (MFE)
- 0.9%
- Max adverse move (MAE)
- 14.3%